Qingsong Zhu, Ph.D., is the Chief Operating Officer of Insilico Medicine. Dr. Zhu received his doctorate in biochemistry from Kansas State University. As part of his studies, he integrated biochemistry, genomics, and bioinformatics to identify new drug targets for insect control. Before joining Insilico, he also served as a research fellow at the Johns Hopkins University School of Medicine under Dr. Nancy Davidson. His research focused on cancer epigenetic biomarkers and anti-epigenetic cancer drug discovery. He is currently interested in using deep learning to promote biomarker development and drug discovery.